Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medtronic Sees Long-Awaited Approval Of MiniMed 530G As A Big Step In Artificial Pancreas “Journey”

This article was originally published in The Gray Sheet

Executive Summary

Medtronic recently announced FDA approval of its MiniMed 530G low-glucose-suspend insulin pump, the first system approved in the U.S. that can automatically stop insulin delivery when blood glucose levels fall to a pre-set level.


Related Content

Tandem Diabetes Adds Special Touch (Screen) To Integrated Pump-Monitor Space
Medtronic Launches Predictive MiniMed 640G Insulin Pump Outside The U.S.
Medtronic Launches U.S. Trial For Predictive Glucose Monitor-Pump System
Medtronic Gets Extra FDA Attention To Hasten Approval Of Next-Gen Insulin Pump
Medtronic Anticipates Turnaround For Challenged Business Units
New Product Briefs: PCI Tools Launch; Asthma Device In China
News Briefs: Medtronic’s First-Gen Artificial Pancreas Approved; CMS Removes Bariatric Surgery Requirements
Positive Data For Threshold-Suspend Feature Of Medtronic Insulin Pump
FDA Audit Slows Down Medtronic Launch Plans For Low-Glucose-Suspend Diabetes System
Diabetes Researchers Say FDA Is Slowing Artificial Pancreas Efforts





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts